Federal Circuit: No Rehearing After Inhaler Patent Delisting Affirmation
WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals rejected a rehearing petition from Teva Branded Pharmaceutical Products R&D Inc. and related entities, leaving in place a panel’s December opinion...To view the full article, register now.
Already a subscriber? Click here to view full article